Discovery of riociguat (BAY 63-2521): a potent, oral stimulator of soluble guanylate cyclase for the treatment of pulmonary hypertension

Ítems similars

• Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
  per: Frey, Reiner, et al.
  Publicat: (2009)
• Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
  per: Frey, Reiner, et al.
  Publicat: (2016)
• Cardio-renal protection of riociguat (BAY 63-2521) in low- and high-renin models of hypertension
  per: Kalk, Philipp, et al.
  Publicat: (2009)
• No pharmacodynamic (PD) and pharmacokinetic (PK) interaction of riociguat (BAY 63-2521) and aspirin
  per: Frey, Reiner, et al.
  Publicat: (2011)
• Absorption of riociguat (BAY 63-2521): bioavailability, food effects, and dose proportionality
  per: Becker, Corina, et al.
  Publicat: (2016)